WO1994024115A1 - Nouveau derive de piperazine - Google Patents
Nouveau derive de piperazine Download PDFInfo
- Publication number
- WO1994024115A1 WO1994024115A1 PCT/JP1994/000614 JP9400614W WO9424115A1 WO 1994024115 A1 WO1994024115 A1 WO 1994024115A1 JP 9400614 W JP9400614 W JP 9400614W WO 9424115 A1 WO9424115 A1 WO 9424115A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- groups
- compound
- phenylethyl
- lower alkyl
- Prior art date
Links
- 150000004885 piperazines Chemical class 0.000 title description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 189
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 37
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 29
- 150000003839 salts Chemical class 0.000 claims abstract description 22
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 16
- 125000002947 alkylene group Chemical group 0.000 claims abstract description 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 11
- 125000003342 alkenyl group Chemical group 0.000 claims abstract description 9
- 125000005530 alkylenedioxy group Chemical group 0.000 claims abstract description 8
- 125000000304 alkynyl group Chemical group 0.000 claims abstract description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 7
- -1 phenyloxy Chemical group 0.000 claims description 64
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 18
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 13
- 125000005843 halogen group Chemical group 0.000 claims description 12
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 10
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 229910052731 fluorine Inorganic materials 0.000 claims description 8
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 7
- 230000004064 dysfunction Effects 0.000 claims description 7
- 125000001153 fluoro group Chemical group F* 0.000 claims description 7
- 229940124597 therapeutic agent Drugs 0.000 claims description 7
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 6
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 230000002490 cerebral effect Effects 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 2
- 210000005036 nerve Anatomy 0.000 claims description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 10
- 206010012289 Dementia Diseases 0.000 abstract description 9
- 201000000980 schizophrenia Diseases 0.000 abstract description 7
- 208000019901 Anxiety disease Diseases 0.000 abstract description 6
- 208000025865 Ulcer Diseases 0.000 abstract description 4
- 230000036506 anxiety Effects 0.000 abstract description 4
- 231100000397 ulcer Toxicity 0.000 abstract description 4
- 230000002124 endocrine Effects 0.000 abstract description 3
- 230000001079 digestive effect Effects 0.000 abstract description 2
- 208000019736 Cranial nerve disease Diseases 0.000 abstract 1
- 208000014826 cranial nerve neuropathy Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 102
- 239000000243 solution Substances 0.000 description 51
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 45
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 30
- 239000000203 mixture Substances 0.000 description 27
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 24
- 238000006243 chemical reaction Methods 0.000 description 24
- 238000000034 method Methods 0.000 description 23
- 108020003175 receptors Proteins 0.000 description 23
- 102000005962 receptors Human genes 0.000 description 23
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 22
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 21
- 238000012360 testing method Methods 0.000 description 19
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- 239000012528 membrane Substances 0.000 description 17
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 239000012044 organic layer Substances 0.000 description 14
- 230000027455 binding Effects 0.000 description 12
- 238000000354 decomposition reaction Methods 0.000 description 12
- 239000003921 oil Substances 0.000 description 12
- 235000019198 oils Nutrition 0.000 description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
- 238000010898 silica gel chromatography Methods 0.000 description 12
- 230000009870 specific binding Effects 0.000 description 12
- 239000000872 buffer Substances 0.000 description 10
- XWBDWHCCBGMXKG-UHFFFAOYSA-N ethanamine;hydron;chloride Chemical compound Cl.CCN XWBDWHCCBGMXKG-UHFFFAOYSA-N 0.000 description 10
- 239000003446 ligand Substances 0.000 description 10
- 229910052757 nitrogen Inorganic materials 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 9
- 210000004556 brain Anatomy 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- 108010085082 sigma receptors Proteins 0.000 description 7
- 235000009518 sodium iodide Nutrition 0.000 description 7
- 125000001424 substituent group Chemical group 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 235000003332 Ilex aquifolium Nutrition 0.000 description 6
- 241000209027 Ilex aquifolium Species 0.000 description 6
- 229940126214 compound 3 Drugs 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 210000003792 cranial nerve Anatomy 0.000 description 6
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 6
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 230000009871 nonspecific binding Effects 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 5
- CVVIJWRCGSYCMB-UHFFFAOYSA-N hydron;piperazine;dichloride Chemical compound Cl.Cl.C1CNCCN1 CVVIJWRCGSYCMB-UHFFFAOYSA-N 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 125000004193 piperazinyl group Chemical group 0.000 description 5
- LGQCVMYAEFTEFN-DQYPLSBCSA-N tocris-1079 Chemical compound C1C2=CC=C(O)C=C2[C@]2(C)[C@H](C)[C@H]1N(CC=C)CC2 LGQCVMYAEFTEFN-DQYPLSBCSA-N 0.000 description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 5
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 4
- RMAFFDDZXBTOQO-SPIKMXEPSA-N (Z)-but-2-enedioic acid piperazine Chemical compound C1CNCCN1.OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O RMAFFDDZXBTOQO-SPIKMXEPSA-N 0.000 description 4
- RQEUFEKYXDPUSK-UHFFFAOYSA-N 1-phenylethylamine Chemical compound CC(N)C1=CC=CC=C1 RQEUFEKYXDPUSK-UHFFFAOYSA-N 0.000 description 4
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- 239000002480 mineral oil Substances 0.000 description 4
- 235000010446 mineral oil Nutrition 0.000 description 4
- 125000004430 oxygen atom Chemical group O* 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000012312 sodium hydride Substances 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- ZMNPFYANVKDFQC-OAHLLOKOSA-N (1s)-1-phenyl-2-phenylmethoxyethanamine Chemical compound C([C@@H](N)C=1C=CC=CC=1)OCC1=CC=CC=C1 ZMNPFYANVKDFQC-OAHLLOKOSA-N 0.000 description 3
- HPZJMUBDEAMBFI-WTNAPCKOSA-N (D-Ala(2)-mephe(4)-gly-ol(5))enkephalin Chemical compound C([C@H](N)C(=O)N[C@H](C)C(=O)NCC(=O)N(C)[C@@H](CC=1C=CC=CC=1)C(=O)NCCO)C1=CC=C(O)C=C1 HPZJMUBDEAMBFI-WTNAPCKOSA-N 0.000 description 3
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108700022183 Ala(2)-MePhe(4)-Gly(5)- Enkephalin Proteins 0.000 description 3
- 208000017701 Endocrine disease Diseases 0.000 description 3
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 3
- 206010061459 Gastrointestinal ulcer Diseases 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 3
- 229960004373 acetylcholine Drugs 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 3
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229940125782 compound 2 Drugs 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 235000008504 concentrate Nutrition 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000000967 suction filtration Methods 0.000 description 3
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 108010025899 gelatin film Proteins 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000011597 hartley guinea pig Methods 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- SKHIBNDAFWIOPB-UHFFFAOYSA-N hydron;2-phenylethanamine;chloride Chemical compound Cl.NCCC1=CC=CC=C1 SKHIBNDAFWIOPB-UHFFFAOYSA-N 0.000 description 2
- FUKUFMFMCZIRNT-UHFFFAOYSA-N hydron;methanol;chloride Chemical compound Cl.OC FUKUFMFMCZIRNT-UHFFFAOYSA-N 0.000 description 2
- 230000009390 immune abnormality Effects 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 201000003723 learning disability Diseases 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- NQPAICOXPNRJSR-UHFFFAOYSA-N n,n-bis(2-chloroethyl)cyclohexanamine;hydrochloride Chemical compound Cl.ClCCN(CCCl)C1CCCCC1 NQPAICOXPNRJSR-UHFFFAOYSA-N 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- DPBLXKKOBLCELK-UHFFFAOYSA-N pentan-1-amine Chemical compound CCCCCN DPBLXKKOBLCELK-UHFFFAOYSA-N 0.000 description 2
- 125000003884 phenylalkyl group Chemical group 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- ZMNPFYANVKDFQC-HNNXBMFYSA-N (1r)-1-phenyl-2-phenylmethoxyethanamine Chemical compound C([C@H](N)C=1C=CC=CC=1)OCC1=CC=CC=C1 ZMNPFYANVKDFQC-HNNXBMFYSA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- OMBVEVHRIQULKW-DNQXCXABSA-M (3r,5r)-7-[3-(4-fluorophenyl)-8-oxo-7-phenyl-1-propan-2-yl-5,6-dihydro-4h-pyrrolo[2,3-c]azepin-2-yl]-3,5-dihydroxyheptanoate Chemical compound O=C1C=2N(C(C)C)C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C(C=3C=CC(F)=CC=3)C=2CCCN1C1=CC=CC=C1 OMBVEVHRIQULKW-DNQXCXABSA-M 0.000 description 1
- IJXJGQCXFSSHNL-QMMMGPOBSA-N (R)-(-)-2-Phenylglycinol Chemical compound OC[C@H](N)C1=CC=CC=C1 IJXJGQCXFSSHNL-QMMMGPOBSA-N 0.000 description 1
- MOHYOXXOKFQHDC-UHFFFAOYSA-N 1-(chloromethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CCl)C=C1 MOHYOXXOKFQHDC-UHFFFAOYSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- UJORPFQWUKFXIE-UHFFFAOYSA-N 2-[1-[(4-ethoxy-2,6-difluorophenyl)methyl]-5,6-dihydro-4h-cyclopenta[c]pyrazol-3-yl]-5-methoxy-n-pyridin-4-ylpyrimidin-4-amine Chemical compound FC1=CC(OCC)=CC(F)=C1CN1C(CCC2)=C2C(C=2N=C(NC=3C=CN=CC=3)C(OC)=CN=2)=N1 UJORPFQWUKFXIE-UHFFFAOYSA-N 0.000 description 1
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- MROVZCRMXJZHCN-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-(2-hydroxyethyl)benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCCO)C=CC=1 MROVZCRMXJZHCN-UHFFFAOYSA-N 0.000 description 1
- HAAZMOAXEMIBAJ-UHFFFAOYSA-N 4-chloro-2-methylquinazoline Chemical compound C1=CC=CC2=NC(C)=NC(Cl)=C21 HAAZMOAXEMIBAJ-UHFFFAOYSA-N 0.000 description 1
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- WLEYNPGZFNBRFF-SPIKMXEPSA-N C(\C=C/C(=O)O)(=O)O.C(\C=C/C(=O)O)(=O)O.N1=CC=NC=C1 Chemical compound C(\C=C/C(=O)O)(=O)O.C(\C=C/C(=O)O)(=O)O.N1=CC=NC=C1 WLEYNPGZFNBRFF-SPIKMXEPSA-N 0.000 description 1
- CYBLRLSBUDRRFT-UHFFFAOYSA-N C1=CC=C(C=C1)C2C=NC=CN2C3=CC=CC=C3 Chemical class C1=CC=C(C=C1)C2C=NC=CN2C3=CC=CC=C3 CYBLRLSBUDRRFT-UHFFFAOYSA-N 0.000 description 1
- IVHLLQHKCFZHKO-CYBMUJFWSA-N C[C@H](C1=CC=CC=C1)NOCC2=CC=C(C=C2)OC Chemical compound C[C@H](C1=CC=CC=C1)NOCC2=CC=C(C=C2)OC IVHLLQHKCFZHKO-CYBMUJFWSA-N 0.000 description 1
- 101100422770 Caenorhabditis elegans sup-1 gene Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- PLUBXMRUUVWRLT-UHFFFAOYSA-N Ethyl methanesulfonate Chemical compound CCOS(C)(=O)=O PLUBXMRUUVWRLT-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 1
- 208000020358 Learning disease Diseases 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- IIBOGKHTXBPGEI-UHFFFAOYSA-N N-benzylformamide Chemical compound O=CNCC1=CC=CC=C1 IIBOGKHTXBPGEI-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Natural products NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Natural products C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- ZEEBGORNQSEQBE-UHFFFAOYSA-N [2-(3-phenylphenoxy)-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound C1(=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)C1=CC=CC=C1 ZEEBGORNQSEQBE-UHFFFAOYSA-N 0.000 description 1
- ABRVLXLNVJHDRQ-UHFFFAOYSA-N [2-pyridin-3-yl-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound FC(C1=CC(=CC(=N1)C=1C=NC=CC=1)CN)(F)F ABRVLXLNVJHDRQ-UHFFFAOYSA-N 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- QBYJBZPUGVGKQQ-SJJAEHHWSA-N aldrin Chemical compound C1[C@H]2C=C[C@@H]1[C@H]1[C@@](C3(Cl)Cl)(Cl)C(Cl)=C(Cl)[C@@]3(Cl)[C@H]12 QBYJBZPUGVGKQQ-SJJAEHHWSA-N 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000002858 crystal cell Anatomy 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- OKBPCTLSPGDQBO-UHFFFAOYSA-L disodium;dichloride Chemical compound [Na+].[Na+].[Cl-].[Cl-] OKBPCTLSPGDQBO-UHFFFAOYSA-L 0.000 description 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229910052733 gallium Inorganic materials 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229940018158 hydroxypropylcellulose 5 mg Drugs 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical group C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 102000051367 mu Opioid Receptors Human genes 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 1
- 229940100684 pentylamine Drugs 0.000 description 1
- 125000005359 phenoxyalkyl group Chemical group 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000131 polyvinylidene Polymers 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 150000003216 pyrazines Chemical class 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 150000003385 sodium Chemical class 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229910001575 sodium mineral Inorganic materials 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical group CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- AKMXMQQXGXKHAN-UHFFFAOYSA-N titanium;hydrate Chemical compound O.[Ti] AKMXMQQXGXKHAN-UHFFFAOYSA-N 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 108020001612 μ-opioid receptors Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/092—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings with aromatic radicals attached to the chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C07D317/64—Oxygen atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the present invention has an affinity for receptors and receptors, and is used to treat dementia, depression, schizophrenia, anxiety and other cranial nerve dysfunctions, diseases associated with immune and endocrine disorders, and digestive ulcers. It relates to a new compound that is useful as an agent.
- 1,2-diphenylbiperazine derivatives have been studied as analgesics (Japanese Patent Publication No. 47-634, Japanese Patent Publication No. 49-188, J. Med. Chem., _0_1240 (1975)).
- Etc. a substituent in which a substituent such as an alkyl group, an alkenyl group, a cycloalkyl group, or a phenylalkyl group is introduced at the 4-position of the piperazine ring.
- a substituent such as a halogen atom, a hydroxy group, or a lower alkoxy group is added to the phenyl ring.
- the compounds introduced have been reported.
- 1,2-diphenylpyrazine derivatives in which the 4-position of the piperazine ring is substituted with a phenylalkyl group or a phenoxyalkyl group have a calcium antagonism and a cerebral nerve function improvement action ( JP-A-63-141 966, JP-A-3-72229).
- the present inventors focused on the alkylene chain of the diphenylalkylpiperazine derivative, synthesized a novel piperazine derivative having an oxygen atom introduced into the alkylene chain, and examined its pharmacological action.o
- the compound of the present invention is useful for the treatment of cranial nerve dysfunction such as dementia, depression, schizophrenia, and insecurity, diseases associated with immunoreceptor and endocrine disorders, and digestion, It was found to be useful as a therapeutic agent for organ ulcers and the like.
- the present invention provides a novel pyrazine compound represented by the following general formula [I] and a salt thereof (hereinafter, referred to as the compound of the present invention).
- R 1 represents a lower alkyl group, a cycloalkyl group, a phenyl group, a phenyl lower alkyl group or a phenyl lower alkyl group, and a phenyl ring of a phenyl group, a phenyl lower alkyl group or a phenyl lower alkyl group.
- the cycloalkyl group may be substituted with one or more lower alkyl groups, lower alkenyl groups, lower alkynyl groups, hydroxy groups, lower alkoxy groups or lower alkylenedioxy groups.
- R 2 and R 3 are the same or different and represent a hydrogen atom, a halogen atom, a lower alkyl group, a hydroxy group, a lower alkoxy group or a cyano group.
- a and B are the same or different and represent a lower alkylene group. You.
- n 0 or 1. same as below. ]
- lower alkyl is a straight chain having 1 to 6 carbon atoms such as methyl, ethyl, propyl, hexyl, isopropyl, and teft.-butyl.
- a branched alkyl, and a lower alkenyl is a straight-chain or branched alkenyl having 2 to 6 carbon atoms containing a double bond such as vinyl, aryl, and hexenyl
- a lower alkynyl is Represents a straight-chain or branched alkynyl having 2 to 6 carbon atoms containing a triple bond such as ethynyl, propynyl, hexynyl and the like.
- Lower alkoxy is methoxy, ethoxy, propoxy, hexyloxy, Is a straight-chain or branched alkoxy having 1 to 6 carbon atoms such as isopropoxy, tert.-butoxy, etc.
- cycloalkyl is cyclopropyl, cyclolob.
- Cycloalkyl having 3 to 8 carbon atoms such as cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl
- lower alkylene means methylene, ethylene, (dimethyl) It represents a straight-chain or branched alkylene having 1 to 6 carbon atoms such as methylene, (methyl) methylene and the like.
- the lower alkylenedioxy is methylenedioxy, ethylenedioxy, (dimethyl) methylenedioxy, (getyl).
- the salts include pharmaceutically acceptable salts such as hydrochloride, sulfate, maleate and fumarate.
- R 1 is a lower alkyl group, a cycloalkyl group, a phenyl group, a phenyl lower alkyl group or a phenyloxy lower alkyl group, and Is different and includes a compound of a hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxy group or a cyano group. More preferred examples include R 1 is a cyclohexyl group or a phenylethyl group, R 2 is a hydrogen atom or a halogen atom,
- R 3 is a compound represented by a hydrogen atom, a halogen atom or a lower alkoxy group.
- R 2 is a hydrogen atom or a fluorine atom
- R 3 is a hydrogen atom, a fluorine atom or a methoxy group.
- the lower alkylene group of A and B is preferably a methylene group.
- Examples of the compounds of the present invention which have particularly excellent effects include 1- (2-benzyloxy-1-1-phenylethyl) -4-cyclohexylbiperazine, 1- (1-benzyloxymethyltinole-2—phenylethyl 1) 4—cyclohexylolepiperazine, 4—cyclohexyl 1 1— [2— (4—fluorobenziloxoxy) 1—1-phenylenyl) piperazine, 4—cyclohexyl 1—1—2— (4— —Methoxybenzyloxy) 1- 1-phenylethyl) piperazine and 1- (2—benzyloxy 1- 1-phenylethyl) 1-4- (2—phenylethyl) piperazine, and the respective salts And stereoisomers and optically active isomers.
- Representative methods for synthesizing the compounds of the present invention include the following a) and b) ⁇ )
- R 4 represents a protecting group for an amino group such as a lower alkanoyl group or a lower alkoxycarbonyl group
- X represents a leaving group such as a halogen atom or a lower alkane sulfonyloxy group.
- the amino group of the compound represented by the formula [11] is protected to give a compound of the formula [111], and the compound of the formula [IV] is reacted with the compound of the formula [IV] to obtain a compound of the formula [11]
- the compound of formula [V] is converted to the compound of formula [V], and then the protecting group for the amino group is removed to obtain a compound of formula [VI].
- the compound of formula [VII] is reacted with a compound of formula [VII] to form a piperazine ring. To obtain the compound [I] of the present invention.
- the method of b) comprises reacting the compound of formula [VI] obtained by the method of a) with a halogenated alcohol such as 2-bromoethanol to give the compound of formula [VI] with the compound of formula [V111]. After that, thionyl chloride or methanesulfonyl chloride or the like is reacted therewith, the compound of the formula [V111] is led to the compound of the formula [], and then R 1 NH 2 is reacted to form a piperazine ring. To obtain the compound [I] of the present invention.
- a halogenated alcohol such as 2-bromoethanol
- the compound obtained by the above method can be converted into a salt as described above by a conventional method.
- the compound represented by the general formula [I] has optical isomers, all of which are included in the present invention.
- an optically active material When an optically active material is used, an optically active substance can be obtained.However, when a racemic substance is used as a raw material, a racemic product can be optically separated using an optical resolving agent or the like. it can.
- Et al is, [3 ⁇ ] (+) - ⁇ where the T Zeta was as a labeled ligand consider the affinity, the compounds of the present invention [3 ⁇ ] (+) - SKF - 1 0 0 4 7 of As in the case, it showed strong affinity for the ⁇ receptor.
- an experiment was performed to determine whether the compound of the present invention exhibits a morphine-like effect. It is known that a compound having a morphine-like action has a strong affinity for a ⁇ receptor, and if the affinity for a receptor is weak, it can be determined that the compound has a weak morphine-like action.
- the affinity of the compound of the present invention for the ⁇ receptor was examined using [ 3 H] DAMG0 as a labeled ligand. As a result, it was found that the compound of the present invention has a weak affinity for the // receptor, and the compound of the present invention does not substantially exhibit a morphine-like effect.
- the difference between the effect expression amount and the side effect expression amount is large. That is, in the present invention, it is preferable that the affinity for the ⁇ receptor is strong and the affinity for the ⁇ receptor is weak, and the experimental results described below show that the compound of the present invention is excellent as a pharmaceutical. It proves.
- a learning disorder model due to ischemia which is known as a disease model of dementia due to cerebrovascular disorders, that is, four arteries are obtained by the method of Pulsinel li (Stroke, H, 267-272 (1979)).
- Pulsinel li Pulsinel li
- the compound of the present invention had an improving effect on learning disability.
- a compound that increases the amount of acetylcholine in the brain was dementia. J. Med, 315, 1241-1245 (1986)), it was reported by Matsuno et al. (Brain Res., 575, 315-). 319 (1992))
- the compound of the present invention showed an effect of increasing acetylcholine.
- the compound of the present invention shows that the compound of the present invention is a disease involving dementia, depression, schizophrenia, anxiety, etc. It has a wide range of pharmaceutical uses as a therapeutic agent for organ ulcers and the like, and is particularly useful as a therapeutic agent for cranial nerve dysfunction.
- the method of administration of the compound of the present invention may be oral or parenteral.
- the dosage form include tablets, capsules, soft capsules, granules, and injections.
- the compound of the present invention can be formulated using a technique that is widely used.
- oral preparations such as tablets, capsules, soft capsules, and granules may be used, if necessary, in lactose, starch, crystal cell mouth, bulking agents such as vegetable oils, lubricating agents such as magnesium stearate, talc, etc.
- Binders such as hydroxypropylcellulose and polyvinylidene, disintegrants such as low-substituted hydroxypropylcellulose mouth, calcium carboxymethylcellulose, hydroxypropylmethylcellulose, macrogol, silicone It can be formulated using a coating agent such as a resin or a film agent such as a gelatin film.
- the dosage is appropriately selected depending on the symptoms, dosage form, etc., but usually 1 mg to 100 mg, preferably 1 mg to 200 mg per day may be administered once or in several divided doses.o
- N, N-bis (2-chloroethyl) cyclohexylamine hydrochloride (0.75 g) dimethyl formamide (0.71 g) of nilethylamine (Reference compound 41, 0.65 g) (40 ml), add sodium iodide (0.886 g) and potassium carbonate (1.19 g) to the solution, and stir at 60 ° C for 5 hours.
- the organic layer is washed with water and saturated saline, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure.
- the obtained oil is purified by silica gel column chromatography, ethanol ethanolic hydrochloride solution is added, and the mixture is concentrated under reduced pressure to obtain 0.69 g (53%) of the title compound (compound 3-1).
- Example 3 The same operation as in Example 3 is performed to obtain the following compound.
- the membrane preparation was prepared by the following method according to the paper by Tam et al. (Proc. Natl. Acad. Sci. USA, Jl ⁇ 703-670? (1983)).
- the specific binding amount of [ ⁇ ⁇ ] (+) — SKF— 10047 was determined in advance by the following method. Doo Risu membrane specimen suspended in HCl buffer, bets squirrel - was dissolved in hydrochloric acid buffer solution [3 ⁇ ] (+) - SKF - 1 0 0 4 7 (5 ⁇ ⁇ ) was added (test compound The reaction was carried out at 25 ° C. for 30 minutes. After completion of the reaction, the reaction solution was subjected to suction filtration with a glass filter, and the radioactivity on the filter was measured with a liquid scintillation counter to determine the total binding amount.
- (+) — SKF— 100 4 7 A mixture of (5 nM) and (+)-SKF-10047 (100 M) without radioactivity was added (without adding the test compound), and the membrane was labeled using the same method as above. The amount of binding to the product was determined, and the result was defined as the amount of non-specific binding. The difference between the total binding amount and the non-specific binding amount thus obtained was defined as the specific binding amount.
- Table 1 shows the results of Compound 1-1, Compound 2-1, Compound 3-1, and Compound 3-5 as examples of the experimental results.
- the compound of the present invention was found to significantly inhibit the specific binding amount of [ 3 H] (+)-SKF-107 at a low concentration. It was found to have strong affinity for the sigma receptor.
- the membrane preparation was prepared according to the following method according to a paper by Tam et al. (Proc. Natl., Acad. Sci. USA, 80, 6703-6707 (1983)).
- the brain is removed from a Hartley guinea pig (body weight: 300-400 g), and a tris-hydrochloric acid buffer (5 OmM, pH 7.7, 0. After homogenization in 32 M sucrose), the mixture was centrifuged to obtain a supernatant. The pellet obtained by ultracentrifuging the supernatant for 20 minutes is suspended in Tris-monohydrochloride buffer (50 mM, pH 7.7, the same applies hereinafter), and centrifuged again to obtain a membrane. A sample was obtained.
- Table 2 shows the results of compound 3-1, compound 3-5, compound 5-1, and compound 5-2 as an example of the experimental results.
- the membrane preparation was prepared by the following method according to the paper by Kosterli et al. (Br. J. Pharmac., 68, 333-342 (1980)).
- Brain is removed from a Wistar male rat (body weight: about 300 g), and is dissolved in Tris-HCl buffer (50 mM, pH 7.7, the same applies hereinafter) 20 times the brain weight. After homogenizing with, ultracentrifugation was performed for 15 minutes to obtain pellets. This pellet was suspended in a Tris-HCl buffer, incubated at 37 ° C for 30 minutes, and ultracentrifuged for 15 minutes to obtain a pellet, which was used as a membrane sample.
- Tris-HCl buffer 50 mM, pH 7.7, the same applies hereinafter
- the specific binding amount of [ 3 H] DAMG0 was determined in advance by the following method. Doo Risu membrane specimen suspended in HCl buffer, Application Benefits scan - dissolved in hydrochloric acid buffer solution [3 H] D AM GO to (1 n M) was added (test compound without added), 2 5 The reaction was carried out at 30 ° C for 30 minutes. After completion of the reaction, the reaction solution was subjected to suction filtration with a glass filter, and the radioactivity on the filter was measured with a liquid scintillation counter to determine the total binding amount.
- Table 3 shows the results of Compound 11-1, Compound 2-1, Compound 3-1, and Compound 3-5 as examples of the experimental results.
- the compound of the present invention has a strong affinity for the bireceptor, shows almost no morphine-like action, and is a disease involving the receptor such as dementia, depression, and schizophrenia. It has a wide range of medical uses as a therapeutic agent for cranial nerve dysfunction such as anxiety disorders, diseases associated with immune abnormalities and endocrine abnormalities, and gastrointestinal ulcers. It proved to be useful.
- the present invention has an affinity for the receptor, dementia, It is intended to provide a novel compound useful as a therapeutic agent for cranial nerve dysfunction such as depression, schizophrenia and anxiety disorder, a disease associated with immune abnormality and endocrine abnormality, and gastrointestinal ulcer.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Abstract
Composé représenté par la formule générale (I), ainsi que ses sels. Dans ladite formule, R1 représente alkyle inférieur, cycloalkyle, phényle, alkyle inférieur à substitution phénylique ou bien alkyle inférieur à substitution phénoxique, où le cycloalkyle, phényle et les groupes phényle de l'alkyle inférieur à substitution phénylique et de l'alkyle inférieur à substitution phénoxique peuvent être substitués par un ou plusieurs groupes alkyle inférieur, alcényle inférieur, alcynyle inférieur, hydroxy, alcoxy inférieur ou alkylènedioxy inférieur; R2 et R3 représentent chacun indépendamment hydrogène, halogène, alkyle inférieur, hydroxy, alcoxy inférieur ou cyano; A et B représentent chacun indépendamment alkylène inférieur; et n représente 0 ou 1. Ce composé est utile comme remède contre les troubles fonctionnels des nerfs craniens, tels que la démence, la dépression, la schizophrénie et l'anxiété, les affections associées à l'immunopathologie et à l'anomalie endocrinienne, ainsi que les ulcères à l'estomac.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP8964193 | 1993-04-16 | ||
JP5/89641 | 1993-04-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994024115A1 true WO1994024115A1 (fr) | 1994-10-27 |
Family
ID=13976406
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1994/000614 WO1994024115A1 (fr) | 1993-04-16 | 1994-04-12 | Nouveau derive de piperazine |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP3077047B2 (fr) |
WO (1) | WO1994024115A1 (fr) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2883970B2 (ja) | 1993-07-28 | 1999-04-19 | 参天製薬株式会社 | 新規1,4−(ジフェニルアルキル)ピペラジン誘導体 |
US6713626B2 (en) | 2002-03-12 | 2004-03-30 | Wyeth | Process for synthesizing N-aryl piperazines with chiral N′-1-[benzoyl(2-pyridyl)amino]-2-propane substitution |
US6784294B2 (en) | 2002-03-12 | 2004-08-31 | Wyeth | Preparation of N1-(2′-pyridyl)-1,2-propanediamine sulfamic acid and its use in the synthesis of biologically active piperazines |
US6916797B2 (en) * | 1999-12-20 | 2005-07-12 | Ucb, S.A. | α-arylethylpiperazine derivatives as neurokinin antagonists |
US7019137B2 (en) | 2002-03-12 | 2006-03-28 | Wyeth | Process for making chiral 1,4-disubstituted piperazines |
US7091349B2 (en) | 2002-03-12 | 2006-08-15 | Wyeth | Process for synthesizing N-aryl piperazines with chiral N′-1-[benzoyl(2-pyridyl)amino]-2-propane substitution |
US7361773B2 (en) | 2002-03-12 | 2008-04-22 | Wyeth | Preparation of N1-(2'-pyridyl)-1,2-propanediamine sulfamic acid and its use in the synthesis of biologically active piperazines |
CN103420865A (zh) * | 2013-08-27 | 2013-12-04 | 罗梅 | 一种手性酰胺晶体化合物的制备及合成方法 |
CN103570578A (zh) * | 2013-11-17 | 2014-02-12 | 罗梅 | 一种手性酰胺晶体化合物的合成方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH037229A (ja) * | 1989-03-15 | 1991-01-14 | Santen Pharmaceut Co Ltd | 脳神経機能改善剤 |
WO1991009594A1 (fr) * | 1989-12-28 | 1991-07-11 | Virginia Commonwealth University | Ligands de recepteur sigma et leur emploi |
EP0566189A1 (fr) * | 1992-04-13 | 1993-10-20 | Akzo N.V. | Dérivé de pipérazine psychotropique |
-
1994
- 1994-04-12 WO PCT/JP1994/000614 patent/WO1994024115A1/fr active Application Filing
- 1994-04-12 JP JP06072358A patent/JP3077047B2/ja not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH037229A (ja) * | 1989-03-15 | 1991-01-14 | Santen Pharmaceut Co Ltd | 脳神経機能改善剤 |
WO1991009594A1 (fr) * | 1989-12-28 | 1991-07-11 | Virginia Commonwealth University | Ligands de recepteur sigma et leur emploi |
EP0566189A1 (fr) * | 1992-04-13 | 1993-10-20 | Akzo N.V. | Dérivé de pipérazine psychotropique |
Non-Patent Citations (1)
Title |
---|
CHEMICAL ABSTRACTS, Vol. 88 (21), 145965v, (1978). * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2883970B2 (ja) | 1993-07-28 | 1999-04-19 | 参天製薬株式会社 | 新規1,4−(ジフェニルアルキル)ピペラジン誘導体 |
US6916797B2 (en) * | 1999-12-20 | 2005-07-12 | Ucb, S.A. | α-arylethylpiperazine derivatives as neurokinin antagonists |
CN1304388C (zh) * | 2002-03-12 | 2007-03-14 | 惠氏公司 | 合成手性n-芳基哌嗪的方法 |
US6784294B2 (en) | 2002-03-12 | 2004-08-31 | Wyeth | Preparation of N1-(2′-pyridyl)-1,2-propanediamine sulfamic acid and its use in the synthesis of biologically active piperazines |
US7019137B2 (en) | 2002-03-12 | 2006-03-28 | Wyeth | Process for making chiral 1,4-disubstituted piperazines |
US7091349B2 (en) | 2002-03-12 | 2006-08-15 | Wyeth | Process for synthesizing N-aryl piperazines with chiral N′-1-[benzoyl(2-pyridyl)amino]-2-propane substitution |
US6713626B2 (en) | 2002-03-12 | 2004-03-30 | Wyeth | Process for synthesizing N-aryl piperazines with chiral N′-1-[benzoyl(2-pyridyl)amino]-2-propane substitution |
US7256289B2 (en) | 2002-03-12 | 2007-08-14 | Wyeth | Process for making chiral 1,4-disubstituted piperazines |
US7361773B2 (en) | 2002-03-12 | 2008-04-22 | Wyeth | Preparation of N1-(2'-pyridyl)-1,2-propanediamine sulfamic acid and its use in the synthesis of biologically active piperazines |
CN103420865A (zh) * | 2013-08-27 | 2013-12-04 | 罗梅 | 一种手性酰胺晶体化合物的制备及合成方法 |
CN103420865B (zh) * | 2013-08-27 | 2015-08-26 | 罗梅 | 一种手性酰胺晶体化合物的制备及合成方法 |
CN103570578A (zh) * | 2013-11-17 | 2014-02-12 | 罗梅 | 一种手性酰胺晶体化合物的合成方法 |
CN103570578B (zh) * | 2013-11-17 | 2015-01-14 | 罗梅 | 一种手性酰胺晶体化合物的合成方法 |
Also Published As
Publication number | Publication date |
---|---|
JP3077047B2 (ja) | 2000-08-14 |
JPH06345746A (ja) | 1994-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1995004050A1 (fr) | Nouveau derive de 1,4-di(phenylalkyl)piperazine | |
JP6476205B2 (ja) | RORγ修飾因子としてのヘテロ環式スルホン | |
US5340831A (en) | Muscarinic receptor antagonists | |
US6071932A (en) | Carbazolypiperines as GABA uptake inhibitors | |
AU650421B2 (en) | Medicaments useful in cancer therapy and having antihistaminic properties | |
EP0610793A1 (fr) | Dérivés de morpholine tétracycliques et leur utilisation comme analgésiques | |
JPH0684370B2 (ja) | ムスカリンレセプター拮抗薬 | |
JP4076234B2 (ja) | テトラヒドロベンズインドール化合物 | |
RU2169147C2 (ru) | ПРОИЗВОДНЫЕ АМИДОВ КАРБОНОВЫХ КИСЛОТ С ГЕТЕРОЦИКЛИЧЕСКИМИ ЗАМЕСТИТЕЛЯМИ И КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ СПОСОБНОСТЬЮ ИНГИБИРОВАТЬ 5-HT1А, И/ИЛИ α1, И/ИЛИ α2A, И/ИЛИ α2D, И/ИЛИ D2 РЕЦЕПТОРЫ | |
WO1994024115A1 (fr) | Nouveau derive de piperazine | |
EP0612730B1 (fr) | O-Aryléthers de morphinane | |
US5935955A (en) | Pharmaceutical piperazine compounds | |
EP0816338B1 (fr) | Derives de 3-(bis-phenylmethylene substitue) oxindole | |
US5760035A (en) | Therapeutic agents | |
EP0441852B1 (fr) | Antagonistes recepteurs muscariniques | |
PT96084B (pt) | Processo para a preparacao de ciclo-hexenos substituidos utilizados como agentes do sistema nervoso central | |
Di Giacomo et al. | A new synthesis of carboxyterfenadine (fexofenadine) and its bioisosteric tetrazole analogs | |
JP2883970B2 (ja) | 新規1,4−(ジフェニルアルキル)ピペラジン誘導体 | |
US5932594A (en) | Muscarinic receptor antagonists | |
JPH1171350A (ja) | ヒドロキシピペリジン化合物およびその剤 | |
US5639775A (en) | 4-[4'-piperodinyl or 3'-pirrolidinyl] substituted imidazoles as H3 -receptor antagonists and therapeutic uses thereof | |
DE69903627T2 (de) | Tetrahydroisochinolinderivate als modulatoren von dopamin d3 rezeptoren | |
US5198452A (en) | Styryl phridyl compounds and their pharmaceutical compositions | |
CA2259218C (fr) | Composes de tetrahydrobenzindole | |
JP2920727B2 (ja) | 新規1,4−(ジフェニルアルキル)ホモピペラジン誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA CN FI KR NO US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: CA |
|
122 | Ep: pct application non-entry in european phase |